Notably, data for AstraZeneca’s Lynparza, Johnson & Johnson’s Zytiga, and Loxo Oncology’s larotrectinib highlights the move toward specialized medicine.
Saturday at ASCO: Trial results reveal promising data for combo I-O drugs but no home runs
This includes concerns about the effectiveness — and cost-effectiveness — of drugs like Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo, in combination or alone.
The FDA says Puma’s breast-cancer drug is effective, cautions about side effects
A loaded hemophilia A drug market is an indication patients in and around it are well-served, but that hasn’t stopped contenders such as Roche’s emicizumab.
Lexicon developing type 1 diabetes treatment with Sanofi